Mizuho Maintains Outperform on Medline, Lowers Price Target to $45
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Mizuho analyst Steven Valiquette maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $48 to $45.
Mizuho analyst Steven Valiquette maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $48 to $45.